Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: "Scott W. Lowe" Clear advanced filters

  • Five studies show that disabling p53, an essential tumour-suppressor protein, improves the efficiency of stem-cell production. Are these results a 'heads up' that cancer cells and stem cells are disturbingly similar?

    • Valery Krizhanovsky
    • Scott W. Lowe
    News & Views
    Nature
    Volume: 460, P: 1085-1086

  • The finding that genes encoding enzymes that modify histone proteins are among the targets of certain mutant forms of the p53 protein sheds light on how these mutations cause cancer beyond p53 inactivation. See Article p.206

    • Carol Prives
    • Scott W. Lowe
    News & Views
    Nature
    Volume: 525, P: 199-200

  • Several recent papers have shown that the miR-34 family of microRNAs is directly involved in mediating the effects of p53, indicating that non-coding RNAs have an important role in tumorigenesis. This Progress article discusses these papers and their implications.

    • Lin He
    • Xingyue He
    • Gregory J. Hannon
    Reviews
    Nature Reviews Cancer
    Volume: 7, P: 819-822

  • Normal cells can respond to expression of activated oncogenes by initiating cellular senescence, a permanent state of proliferative arrest. But whether this process reflects a relevant anticancer mechanism has been debated. Several studies now show that oncogene-induced senescence can occur in vivo and provides a bona fide barrier to tumorigenesis.

    • Masashi Narita
    • Scott W Lowe
    News & Views
    Nature Medicine
    Volume: 11, P: 920-922

  • Orienting cancer drug discovery to the patient requires relating the genetic features of tumors to acquired gene and pathway dependencies and identifying small-molecule therapeutics that target them.

    • Stuart L Schreiber
    • Alykhan F Shamji
    • Bruce A Posner
    Comments & Opinion
    Nature Biotechnology
    Volume: 28, P: 904-906

  • Genomic genetically engineered mouse models (GEMMs) have provided a wealth of information about the genes and factors involved in tumour progression. However, various limitations exist for such models, particularly for preclinical drug development. So, what improvements can the non-germline GEMMs offer?

    • Joerg Heyer
    • Lawrence N. Kwong
    • Lynda Chin
    Reviews
    Nature Reviews Cancer
    Volume: 10, P: 470-480

  • Stable RNA interference by shRNA provides a means to study multiple facets of gene function. Fellman and Lowe explore the rules of implementation of this silencing method in the vertebrate system for achieving maximal knockdown with minimal off-target effects.

    • Christof Fellmann
    • Scott W. Lowe
    Reviews
    Nature Cell Biology
    Volume: 16, P: 10-18